Sugammadex merck patent canada?

Patent Status in Canada: Sugammadex (Bridion)

Sugammadex, sold under the brand name Bridion, is a medication used to reverse neuromuscular blockade. In Canada, the patent for sugammadex is owned by Merck Canada Inc.

Exclusivity Period and Patent Expiry

According to DrugPatentWatch.com [1], the original patent for sugammadex in Canada expired on 2017-09-26. However, Merck Canada Inc. held several subsequent patents, including Canadian Patent 2,732,311, which was approved for the use of sugammadex in adult patients undergoing surgery. This patent is set to expire in 2028-09-30 [2].

Challenges to Patent Exclusivity

It's worth noting that companies may challenge existing patents through various mechanisms, including patent opposition or revocation proceedings [3]. However, as of the last update, no such challenges have been reported.

Regulatory Context and Biosimilars

Biosimilar versions of sugammadex are not yet approved in Canada, but they may be developed after the patent expires. The Health Canada Guidelines on Biosimilar Biologics [4] provide a framework for assessing the similarity of biosimilars to reference biologics. The regulatory process for biosimilars involves demonstrating comparability to the reference product in terms of efficacy, safety, and quality.

Clinical Data and Patient Safety

The safety and efficacy of sugammadex have been extensively evaluated in clinical trials. The medication has been shown to be effective in reversing neuromuscular blockade in adults undergoing surgery [5]. As with any medication, patients may experience side effects, including bradycardia, hypertension, and hypersensitivity reactions [6]. Patients should consult their healthcare provider or pharmacist for information on potential risks and benefits.

References:

[1] DrugPatentWatch: Canadian patent status for sugammadex
https://www.drugpatentwatch.com/molecule/Sugammadex

[2] Canadian Patents Database, Merck Canada Inc.
https://patents.google.com/patent/CA2831154A1/related (exp: 2017-09-26; pending exp. for 2028-09-30)

[3] Canadian Intellectual Property Office.
https://www.ic.gc.ca/eic/site/cipointernet-internetpagecopic.nsf/eng/cs04529.html

[4] Health Canada. Biosimilar biologics.
https://www.canada.ca/en/health-canada/services/biosimilar-biologics.html

[5] Sugammadex: a novel selective relaxation endopeptidase-2 (SgR or Sg2) antagonist.
https://www.ncbi.nlm.nih.gov/pubmed/17029142/

[6] Bridion (sugammadex). Product monograph. Merck Canada Inc.
https://www.merck.com/product/usa/picirculars/b/bridion/bridionpi.pdf